Date(s) - June 22, 2017
12:00 PM - 1:00 PM
Dr. Anthony Boral, chief medical officer of Blueprint Medicines, will provide an update on the clinical development of BLU-285, an investigational medicine being developed for patients with advanced GIST.
The presentation will include updated data from Blueprint Medicines’ ongoing Phase 1 clinical trial of BLU-285 in patients with advanced GIST, which was presented at the American Society of Clinical Oncology conference in Chicago, IL on Monday, June 5th.
Date and Time
Thursday, June 22nd beginning at 12:00 p.m., Eastern Time (9:00 a.m., Pacific Time)
Please connect several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
To access only the audio portion, dial in to 1-855-880-1246 (toll free) or 1-646-558-8656 (US toll).
The webinar ID is 855 846 509.
International numbers are available at:
If you have questions you want Blueprint to answer during the webinar on June 22, please send them to me or email@example.com in advance by June 15.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit http://www.blueprintmedicines.com.